AstraZeneca plc and Merck & Co., Inc.’s Lynparza (olaparib) has reinforced is lead among PARP inhibitors for prostate cancer with the publication of data from the Phase III PROpel trial showing the drug, combined with Johnson & Johnson’s Zytiga (abiraterone) and prednisone, resulted in lower risk of disease progression or death in first-line patients, irrespective of homologous recombination repair (HRR) mutation status.
Consequently, Lynparza stands to potentially gain access to a significantly larger share of the prostate cancer market, given both the...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

